Teladoc Health Inc's stock rose by 7.69% as it crossed above the 20-day SMA, reflecting a positive movement in the context of broader market gains with the Nasdaq-100 up 0.75% and the S&P 500 up 0.53%.
However, this increase occurs amid significant challenges for Teladoc, including intensified competition from major players like Amazon, which threatens its market share. The company's virtual mental health service, BetterHelp, is struggling to retain paying users, raising concerns about its growth strategy in a crowded market. Analysts are cautious about Teladoc's profitability and market position, especially as it faces similar challenges in international expansion.
The implications of these competitive pressures suggest that while the stock has seen a short-term gain, the long-term outlook remains uncertain as the company navigates a highly competitive landscape.
Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.91 USD with a low forecast of 7.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.91 USD with a low forecast of 7.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
12 Hold
0 Sell
Hold
Current: 5.740
Low
7.50
Averages
8.91
High
12.00
Current: 5.740
Low
7.50
Averages
8.91
High
12.00
BofA
Allen Lutz
Neutral
downgrade
$7
2026-01-27
New
Reason
BofA
Allen Lutz
Price Target
$7
AI Analysis
2026-01-27
New
downgrade
Neutral
Reason
BofA analyst Allen Lutz lowered the firm's price target on Teladoc to $7 from $7.50 and keeps a Neutral rating on the shares. Sensor Tower trends suggest Q4 revenue could be tracking in-line with consensus and slightly below the midpoint of Teladoc's guidance, states the analyst, whose lowered price target reflects lower peer multiples.
Goldman Sachs
Buy
downgrade
$9 -> $8
2026-01-16
Reason
Goldman Sachs
Price Target
$9 -> $8
2026-01-16
downgrade
Buy
Reason
Goldman Sachs lowered the firm's price target on Teladoc to $8 from $9 and keeps a Buy rating on the shares. MedTech and Healthcare IT stocks fell sharply from January 8-14, declining about 3% and 11%, respectively, in a move that appears largely disconnected from fundamentals, the analyst tells investors in a research note. Even companies pre-announcing above-consensus results saw share weakness, despite forward outlooks generally at or above current Street expectations, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TDOC
Unlock Now
Citi
Daniel Grosslight
Neutral
downgrade
$10 -> $9
2026-01-09
Reason
Citi
Daniel Grosslight
Price Target
$10 -> $9
2026-01-09
downgrade
Neutral
Reason
Citi analyst Daniel Grosslight lowered the firm's price target on Teladoc to $9 from $10 and keeps a Neutral rating on the shares as part of the firm's 2026 outlook note on the health tech and distribution group. 2025 proved to be another challenging year for health tech, with nearly one-third of the group down greater than 25%, but the firm is "cautiously optimistic" looking ahead to 2026, the analyst tells investors.
Goldman Sachs
David Roman
Buy
downgrade
$10 -> $9
2026-01-09
Reason
Goldman Sachs
David Roman
Price Target
$10 -> $9
2026-01-09
downgrade
Buy
Reason
Goldman Sachs analyst David Roman lowered the firm's price target on Teladoc to $9 from $10 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
